Statements (43)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
Acquired_by_Horizon_Discovery_Group_in_2017
|
| gptkbp:affiliation |
gptkb:FDA
gptkb:NCI EMA |
| gptkbp:awards |
Innovation Award 2020
Excellence in Research 2021 Best_Biotechnology_Company_2019 |
| gptkbp:certifications |
CAP_accredited
CLIA_certified |
| gptkbp:collaborations |
Academic institutions
|
| gptkbp:community_involvement |
Research funding
Health education programs Patient advocacy initiatives |
| gptkbp:employeeCount |
50-100
|
| gptkbp:focus |
Personalized medicine
|
| gptkbp:founded |
2008
|
| gptkbp:founder |
gptkb:Horizon_Discovery_Group
|
| gptkbp:headquarters |
gptkb:Cambridge,_UK
|
| https://www.w3.org/2000/01/rdf-schema#label |
Horizon Diagnostics
|
| gptkbp:industry |
Biotechnology
|
| gptkbp:location |
gptkb:North_America
gptkb:United_Kingdom Europe |
| gptkbp:mission |
Improve patient outcomes
|
| gptkbp:partnerships |
Various pharmaceutical companies
|
| gptkbp:products |
Biologics
Cell lines Genetic assays |
| gptkbp:research |
Therapeutic development
Rare diseases Cancer genomics |
| gptkbp:revenue |
Private company
|
| gptkbp:services |
Genetic testing
Diagnostic_services |
| gptkbp:targetMarket |
Oncology
Clinical research Pharmaceutical development |
| gptkbp:technology |
CRISPR
Cell-based assays Gene_editing |
| gptkbp:vision |
Transforming healthcare through genomics.
|
| gptkbp:website |
www.horizondiagnostics.com
|